

REMARKS

Applicants understand that the amendment in response to the December 23, 2008 Final Office Action has not been entered. By this Amendment, applicants have canceled claims 15, 23 and 24 and amended claim 16. No issue of new matter is raised by these amendments. Accordingly, applicants respectfully request that the Examiner enter and consider these amendments.

Priority

In the Final Office Action, the Examiner indicated that the claimed priority of PCT International Application PCT/IB03/05673, filed December 1, 2003 must be perfected in order for the subject application to have an effective filing date of the December 1, 2003. In response, applicants previously submitted an Application Data Sheet wherein such priority is claimed.

Rejection Under 35 USC § 112, Second Paragraph

The Examiner rejected claims 23 and 24 under 35 U.S.C. 112, second paragraph, as indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. In response, but without conceding the correctness of the Examiner's ground of rejection, applicants have canceled claims 23 and 24 thereby rendering moot the Examiner's ground of rejection.

Rejections in view of Pacioretti and Babish

The Examiner rejected claims 15-22 and 25-28 under 35 U.S.C. 102(e) as anticipated by Pacioretti and Babish, and claims 15, 23 and 24 under 35 U.S.C. 103(a) as obvious over Pacioretti and Babish.

In response, applicants first note that claims 15, 23, and 24 have been canceled thereby rendering moot the Examiner's ground of rejection as to these claims. Applicants respectfully traverse the Examiner's rejection as to claims 16-22 and 25-28.

Pacioretti and Babish disclose a method of treating fat maldistribution resulting from anti-retroviral treatment of HIV-1 infection in a subject comprising administering a pharmaceutically effective dose of a docosahexaenoic acid in combination with a pharmacologically effective dose of a thiol-containing compound or a bioavailable form of trivalent chromium. Pacioretti and

Babish further disclose at paragraph 62 that preferably a daily dose of the present composition would be formulated to deliver about 0.05 to 20 g of conjugated fatty acid per day.

Applicants maintain that the cited prior art does not disclose the claimed invention wherein DHA alone is administered at an amount higher than or equal than to 100 mg/day to a patient concomitantly receiving anti-retroviral therapy is effective in the treatment of lipodystrophy.

In addition, Pacioretti and Babish disclose that the combination of at least 2 ingredients: DHA and a thiol-containing compound or a bioavailable form of trivalent chromium, is the *one effective against fat maldistribution*. Pacioretti and Babish do not disclose, and nowhere can it be derived either explicitly nor implicitly, that *DHA alone* demonstrates this pharmacological and beneficial effect.

In contrast, applicants' invention as recited in amended claim 16 is directed to a method of treatment of lipodystrophy *consisting of* administering an amount higher than or equal to 100 mg/day of DHA alone in a patient simultaneously submitted to antiretroviral therapy.

In view if the remarks above, applicants maintain that Pacioretti and Babish do not anticipate claim 16 as now amended or claims dependent therefrom, and respectfully request that the Examiner reconsider and withdraw this ground of rejection.

Rejection over Holstein et al. in view of Connor et al.

The Examiner rejected claims 15-28 under 35 U.S.C. 103 as obvious over Holstein et al. in view of Connor et al.

In response, applicants again note that claims 15, 23 and 24 have been canceled thereby rendering moot the Examiner's ground of rejection as to these claims. Applicants respectfully traverse the Examiner's ground of rejection as to claims 16-22 and 25-28.

Applicants again respectfully disagree with the Examiner's interpretation that hyperlipidemia is a form of lipodystrophy.

Applicants submit herewith a print-out of MeSH from the U.S. National Library of Medicine's official vocabulary used for indexing articles for MEDLINE/PubMed. According to MeSH, lipodystrophy is defined by:

A collection of heterogenous conditions resulting from defective LIPID METABOLISM and characterized by ADIPOSE TISSUE atrophy. Often there is redistribution of body fat resulting in peripheral fat wasting and central adiposity. They include generalized, localized, congenital, and acquired lipodystrophy.

According to MeSH, hyperlipidemia is defined as: *Conditions with excess LIPIDS in the blood*

In the categories scheme provided by MeSH for “Lipid Metabolism Disorders”, lipodystrophy and hyperlipidemia are presented as different species. The group of hyperlipidemias is categorized by MeSH as a species of dyslipidemias. Dyslipidemias and lipodystrophy are different groups within the genus “Lipid Metabolism Disorder”.

Applicants point out that consistent with the Examiner’s interpretation, lipodystrophy results from defective metabolism of fat, but it is additionally characterized by atrophy or redistribution of body fat. In contrast, hyperlipidemia is characterized by excess lipids in the blood.


Applicants maintain that therefore these two terms deal with different physiological matters, i.e. blood versus adipose tissue, and different concepts, i.e. lipids excess versus redistribution of fat.

Applicants agree that hyperlipidemia may be associated with lipodystrophy, but that this association in no way implies that hyperlipidemia and lipodystrophy are similar or subsets of each other and that an effective treatment for one would be an effective treatment for the other.

In view of the remarks above, applicants maintain that Holstein et al. in view of Connor et al. do not render obvious claim 16 as now amended or claims dependent therefrom, and respectfully request that the Examiner reconsider and withdraw this ground of rejection.

Reconsideration and allowance of all the claims herein are respectfully requested.


Respectfully submitted,



Aude Gerspacher
Registration No. 57,919

May 26, 2009

Cozen O’Connor
250 Park Avenue
New York, New York 10177-0030
Telephone: 212.986.1116;



All Databases
Search MeSH



A service of the National Library of Medicine
and the National Institutes of Health

My NCBI [\[Sign in\]](#) [\[Register\]](#)

PubMed
Nucleotide
Protein
Genome
Structure
OMIM
PMC
Journals
Books

for

Limits
Preview/Index
History
Clipboard
Details

About Entrez
Display: **Full**
Show: 20
Send to

All: 1
 If making selections (e.g., Subheadings, etc.), use the [Send to Search Box](#) feature to see PubMed records with those specifications.

Select PubMed under the Links menu to retrieve all records for the MeSH Term.

Select [NLM MeSH Browser](#) under the Links menu for additional information.

1: Lipid Metabolism Disorders

Pathological conditions resulting from abnormal anabolism or catabolism of lipids in the body.
Year introduced: 2007

Subheadings: This list includes those paired at least once with this heading in MEDLINE and may not reflect current rules for allowable combinations.

blood chemically induced classification complications diagnosis diet therapy drug therapy enzymology epidemiology etiology genetics history immunology metabolism pathology physiopathology prevention and control surgery therapy ultrasonography urine virology

Restrict Search to Major Topic headings only.
 Do Not Explode this term (i.e., do not include MeSH terms found below this term in the MeSH tree).

Entry Terms:

- Lipid Metabolism Disorder
- Metabolism Disorder, Lipid
- Metabolism Disorders, Lipid

[All MeSH Categories](#)

[Diseases Category](#)

[Nutritional and Metabolic Diseases](#)

[Metabolic Diseases](#)

Lipid Metabolism Disorders

- [Dyslipidemias](#)
 - [Hyperlipidemias](#) +
 - [Hypolipoproteinemias](#) +
 - [Smith-Lemli-Optiz Syndrome](#)
- [Lipid Metabolism, Inborn Errors](#)
- [Lipidoses](#)
 - [Cholesterol Ester Storage Disease](#) +
 - [Neuronal Ceroid-Lipofuscinosis](#)
 - [Sjogren-Larsson Syndrome](#)
 - [Sphingolipidoses](#) +
- [Lipodystrophy](#)
 - [HIV-Associated Lipodystrophy Syndrome](#)
 - [Lipodystrophy, Congenital Generalized](#)
 - [Lipodystrophy, Familial Partial](#)
- [Lipomatosis](#)
 - [Adiposis Dolorosa](#)
 - [Lipomatosis, Multiple Symmetrical](#)
- [Xanthomatosis](#)
 - [Xanthomatosis, Cerebrotendinous](#)

Display: **Full**
Show: 20
Send to

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)